Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Columbia University
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Kevin Kalinsky, Columbia University
ClinicalTrials.gov Identifier:
NCT02066532
First received: February 18, 2014
Last updated: October 13, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)